UPDATE 1-Gilead's hepatitis B drug gets U.S. approval

UPDATE 1-Gilead's hepatitis B drug gets U.S. approval


Nov 10 Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration approved its drug to treat chronic hepatitis B infection in patients with scarred liver. The drug, Vemlidy, comes with a boxed warning, the strongest warning issued by the FDA that highlights serious risks such as lactic acid buildup, accumulation of fat on the liver or aggravation of the infection.



from Biotech News